X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
Details:
La Jolla brings to Innoviva an established product portfolio, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections.
Lead Product(s): Angiotensin II
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Giapreza
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 22, 2022
Details:
Acquisition will strengthen Innoviva’s infectious disease portfolio with addition of GIAPREZA® (angiotensin II) and XERAVA® (eravacycline), and advanced late-stage clinical biopharmaceutical company focused on the discovery and development of novel antibacterial products.
Lead Product(s): Angiotensin II
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Giapreza
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Innoviva
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition July 11, 2022
Details:
La Jolla will get double-digit tiered royalty payments based on net sales of GIAPREZA and XERAVA. In exchange, La Jolla granted PAION an exclusive license to commercialize GIAPREZA and XERAVA in the Territories.
Lead Product(s): Angiotensin II
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Giapreza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: PAION UK LTD
Deal Size: $132.0 million Upfront Cash: $22.5 million
Deal Type: Licensing Agreement January 12, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
